Showing 4731-4740 of 8890 results for "".
- Bullous Pemphigoid: The Time to Treat Is Now, Fall Clinical Speakers Sayhttps://practicaldermatology.com/news/bullous-pemphigoid-the-time-to-treat-is-now-fall-clinical-speakers-say/2484090/Earlier recognition of bullous pemphigoid (BP) is critical but safer, targeted treatment options are emerging for this aging and medically fragile patient population, according to a presentation from Donna Culton, MD, PhD, and Prince Adotama, MD, at the 2025 Fall Clinical Dermatology Conference.<
- Dr. Michelle Henry Highlights Noninvasive Periorbital Rejuvenationhttps://practicaldermatology.com/news/dr-michelle-henry-highlights-noninvasive-periorbital-rejuvenation/2483904/Understanding facial aging patterns specific to richly pigmented skin and adjusting treatment approaches accordingly, especially as patient preferences shift away from traditional lower eyelid filler, is key in managing periorbital aging in patients with skin of color, Michelle Henry, MD, FAAD, s
- From EADV: Temtokibart Shows Sustained Efficacy in AD; New DELTA TEEN Datahttps://practicaldermatology.com/news/from-eadv-temtokibart-shows-sustained-efficacy-in-ad-new-delta-teen-data/2483428/LEO Pharma announced data from several important trials and presented updates on delgocitinib LEO Pharma presented phase 2b data for its investigational agent temtokibart (LEO 138559) at the 2025 European Academy of Dermatolo
- LEO To Focus on New Data for CHE, AD, and PsO at EADV 2025https://practicaldermatology.com/news/leo-to-present-data-on-che-ad-and-pso-at-eadv-2025/2483384/LEO Pharma has unveiled its largest-ever scientific program for presentation at the 2025 European Academy of Dermatology and Venereology (EADV) Congress, chronic hand eczema (CHE), atopic dermatitis (AD), and plaque psoriasis, along with updates on investigational a
- Huma Announces AI Tool to Automate Clinical Notes and Billinghttps://practicaldermatology.com/news/huma-announces-ai-tool-to-automate-clinical-notes-and-billing/2475018/Huma Therapeutics announced the launch Hi Scribe, a generative AI tool for automating clinical documentation and billing, according to a press release from the manufacturer. Huma Therapeutics, a UK- and US-based digital healt
- Huma Announces AI Tool to Automate Clinical Notes and Billinghttps://practicaldermatology.com/news/huma-announces-ai-tool-to-automate-clinical-notes-and-billing/2475019/Huma Therapeutics announced the launch Hi Scribe, a generative AI tool for automating clinical documentation and billing, according to a press release from the manufacturer. Huma Therapeutics, a UK- and US-based digital healt
- ADA: Dermatologists Need to Lead on Climate Healthhttps://practicaldermatology.com/news/ada-dermatologists-need-to-lead-on-climate-health/2474867/The American Dermatological Association (ADA) has issued its first comprehensive policy statement on climate change, publishing the document in the Journal of Investigative Dermatology.
- New LED Mask Targets Acne, Redness, Aging in One Sessionhttps://practicaldermatology.com/news/new-led-mask-targets-acne-redness-aging-in-one-session/2474546/Smuuv Body has introduced the Lulu Pro LED Mask in what it says is the first at-home device to deliver five clinically validated wavelengths in a single treatment. A press release from the manufacturer reported that the mask, d
- From ASLMS 2025: Dr. Joel Cohen Highlights New Fractional Laser Techniques, Including Laser-enabled Tissue Coringhttps://practicaldermatology.com/news/from-aslms-dr-joel-cohen-highlights-new-fractional-laser-techniques-for-scars-at-aslms/2474327/During a fractional laser section of the recent program of the 2025 American Society for Laser Medicine and Surgery (ASLMS) Annual Meeting in Orlando, board-certified dermatologist, Mohs surgeon, and laser expert Joel L. Cohen, MD, FAAD, FACMS, presented clinical insights into fractional laser us
- From ASLMS 2025: New Laser Platforms Expand Options for Vascular Rosaceahttps://practicaldermatology.com/news/new-laser-platforms-expand-options-for-vascular-rosacea/2474325/Advanced vascular lasers are transforming the treatment of rosacea by targeting its root cause (chronic vascular dilation) rather than just managing inflammation. At the 2025 American Society for Laser Medicine and Surgery (ASLMS) Annual Meeting in Orlando, Eric Bernstein, MD, Director of